{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:17Z","timestamp":1792622597530,"version":"4.5.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01203-2","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:01:49Z","timestamp":1721142109000},"page":"1983-2038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review"],"prefix":"10.1007","volume":"14","author":[{"given":"Miguel","family":"Mansilla-Polo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-6132","authenticated-orcid":false,"given":"Daniel","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"1203_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","volume":"15","author":"L Quartuccio","year":"2018","unstructured":"Quartuccio L, Zabotti A, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2018;15:87\u201393.","journal-title":"J Adv Res"},{"key":"1203_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/pharmaceutics13010064","volume":"13","author":"D Placha","year":"2021","unstructured":"Placha D, Jampilek J. Chronic inflammatory diseases, anti-inflammatory agents and their delivery nanosystems. Pharmaceutics. 2021;13:64.","journal-title":"Pharmaceutics"},{"key":"1203_CR3","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/S0140-6736(18)31325-4","volume":"391","author":"GL Goll","year":"2018","unstructured":"Goll GL, Kvien TK. New-generation JAK inhibitors: how selective can they be? Lancet. 2018;391:2477\u20138.","journal-title":"Lancet"},{"key":"1203_CR4","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ad.2023.06.012","volume":"114","author":"L Corbella-Bagot","year":"2023","unstructured":"Corbella-Bagot L, Riquelme-McLoughlin C, Morgado-Carrasco D. Long-term safety profile and off-label use of JAK inhibitors in dermatological disorders. Actas Dermosifiliogr. 2023;114:784\u2013801.","journal-title":"Actas Dermosifiliogr"},{"key":"1203_CR5","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, Reid P, Yang V, et al. JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol. 2023;19:1385\u201397.","journal-title":"Expert Rev Clin Immunol"},{"key":"1203_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","volume":"72","author":"JB Galloway","year":"2013","unstructured":"Galloway JB, Mercer LK, Moseley A, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2013;72:229\u201334.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/apt.12182","volume":"37","author":"MD Long","year":"2013","unstructured":"Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1203_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA. 2013;309:887\u201395.","journal-title":"JAMA"},{"key":"1203_CR9","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","volume":"12","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis\u00a0factor therapy for pediatric inflammatory bowel disease: a\u00a0systematic review. Clin Gastroenterol Hepatol. 2014;12:1443\u201351 (quiz e88\u201389).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1203_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00296-014-2945-y","volume":"34","author":"T Cobo-Ib\u00e1\u00f1ez","year":"2014","unstructured":"Cobo-Ib\u00e1\u00f1ez T, Descalzo M\u00c1, Loza-Santamar\u00eda E, et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int. 2014;34:953\u201361.","journal-title":"Rheumatol Int"},{"key":"1203_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/1756-185X.12530","volume":"18","author":"SM Jung","year":"2015","unstructured":"Jung SM, Ju JH, Park MS, et al. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int J Rheum Dis. 2015;18:323\u201330.","journal-title":"Int J Rheum Dis"},{"key":"1203_CR12","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3899\/jrheum.150057","volume":"42","author":"J-W Ai","year":"2015","unstructured":"Ai J-W, Zhang S, Ruan Q-L, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol. 2015;42:2229\u201337.","journal-title":"J Rheumatol"},{"key":"1203_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151:961\u20139.","journal-title":"JAMA Dermatol"},{"key":"1203_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/1756-185X.12970","volume":"20","author":"H Liao","year":"2017","unstructured":"Liao H, Zhong Z, Liu Z, Zou X. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis. 2017;20:161\u20138.","journal-title":"Int J Rheum Dis"},{"key":"1203_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567","volume":"7","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017;7:e012567.","journal-title":"BMJ Open"},{"key":"1203_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.jid.2017.10.005","volume":"138","author":"ZZN Yiu","year":"2018","unstructured":"Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138:534\u201341.","journal-title":"J Invest Dermatol"},{"key":"1203_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12016-017-8623-6","volume":"54","author":"L-Q Hou","year":"2018","unstructured":"Hou L-Q, Jiang G-X, Chen Y-F, et al. The comparative safety of TNF inhibitors in ankylosing spondylitis-a meta-analysis update of 14 randomized controlled trials. Clin Rev Allergy Immunol. 2018;54:234\u201343.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1203_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337-346.e10.","journal-title":"Gastroenterology"},{"key":"1203_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jcpt.12814","volume":"44","author":"V Aydin","year":"2019","unstructured":"Aydin V, Akici A, Isli F, et al. Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: a nationwide cohort study. J Clin Pharm Ther. 2019;44:553\u201360.","journal-title":"J Clin Pharm Ther"},{"key":"1203_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","volume":"3","author":"CT Ritchlin","year":"2019","unstructured":"Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatol. 2019;3:52.","journal-title":"BMC Rheumatol"},{"key":"1203_CR21","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/ibd\/izaa020","volume":"26","author":"CCY Law","year":"2020","unstructured":"Law CCY, Koh D, Bao Y, et al. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2020;26:1796\u2013807.","journal-title":"Inflamm Bowel Dis"},{"key":"1203_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/annrheumdis-2019-216102","volume":"79","author":"X Li","year":"2020","unstructured":"Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79:285\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","volume":"115","author":"S Kedia","year":"2020","unstructured":"Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115:340\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1203_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746396","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, Zhang Z, Wu X, et al. Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis. Front Pharmacol. 2021;12:746396.","journal-title":"Front Pharmacol"},{"key":"1203_CR25","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1001\/jamadermatol.2021.2599","volume":"157","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, et al. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021;157:1056\u201365.","journal-title":"JAMA Dermatol"},{"key":"1203_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis. 2022;81:41\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR27","doi-asserted-by":"publisher","first-page":"adv00648","DOI":"10.2340\/actadv.v102.175","volume":"102","author":"L Davidson","year":"2022","unstructured":"Davidson L, Van den Reek JMPA, Van Hunsel F, et al. Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: spontaneous reports of adverse drug reactions from the World Health Organization Pharmacovigilance Center. Acta Derm Venereol. 2022;102:adv00648.","journal-title":"Acta Derm Venereol"},{"key":"1203_CR28","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/jdv.18407","volume":"36","author":"Y-C Wang","year":"2022","unstructured":"Wang Y-C, Lin Y-H, Ma S-H, et al. Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2022;36:2301\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR29","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/acr.24630","volume":"74","author":"Y Jin","year":"2022","unstructured":"Jin Y, Lee H, Lee MP, et al. Risk of hospitalization for serious infection after initiation of ustekinumab or other biologics in patients with psoriasis or psoriatic arthritis. Arthritis Care Res. 2022;74:1792\u2013805.","journal-title":"Arthritis Care Res"},{"key":"1203_CR30","doi-asserted-by":"publisher","first-page":"2442603","DOI":"10.1155\/2022\/2442603","volume":"2022","author":"Y Feng","year":"2022","unstructured":"Feng Y, Zhou B, Wang Z, et al. Risk of Candida infection and serious infections in patients with moderate-to-severe psoriasis receiving biologics: a systematic review and meta-analysis of randomized controlled trials. Int J Clin Pract. 2022;2022:2442603.","journal-title":"Int J Clin Pract"},{"key":"1203_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13075-022-02842-6","volume":"24","author":"SM Jung","year":"2022","unstructured":"Jung SM, Han M, Kim EH, et al. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013\u20132018. Arthritis Res Ther. 2022;24:157.","journal-title":"Arthritis Res Ther"},{"key":"1203_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/rheumatology\/keac358","volume":"62","author":"B Glintborg","year":"2023","unstructured":"Glintborg B, Di Giuseppe D, Wallman JK, et al. Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatol (Oxford). 2023;62:647\u201358.","journal-title":"Rheumatol (Oxford)"},{"key":"1203_CR33","doi-asserted-by":"publisher","first-page":"1084614","DOI":"10.3389\/fphar.2023.1084614","volume":"14","author":"H Feng","year":"2023","unstructured":"Feng H, Zhao Y, Kuang W, et al. Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: a meta-analysis of randomized, placebo-controlled trials. Front Pharmacol. 2023;14:1084614.","journal-title":"Front Pharmacol"},{"key":"1203_CR34","first-page":"1491","volume":"41","author":"HW Kim","year":"2023","unstructured":"Kim HW, Kim EH, Lee M, et al. Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis and psoriasis treated with IL-17 and TNF-\u03b1 inhibitors: a nationwide nested case-control analysis. Clin Exp Rheumatol. 2023;41:1491\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1203_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2023.105673","volume":"91","author":"M S\u00e9auve","year":"2023","unstructured":"S\u00e9auve M, Aur\u00e9al M, Laplane S, et al. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: a meta-analysis of randomized controlled trials. Jt Bone Spine. 2023;91: 105673.","journal-title":"Jt Bone Spine"},{"key":"1203_CR36","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1111\/jdv.19328","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Zirpel H, Mruwat N, et al. Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors\u2014a population-based study. J Eur Acad Dermatol Venereol. 2023;37:2319\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/ijd.16885","volume":"63","author":"I Lazaridou","year":"2024","unstructured":"Lazaridou I, Vassilopoulos A, Vassilopoulos S, et al. Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators: a systematic review and meta-analysis. Int J Dermatol. 2024;63:139\u201349.","journal-title":"Int J Dermatol"},{"key":"1203_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ibd\/izab092","volume":"28","author":"C Santella","year":"2022","unstructured":"Santella C, Bitton A, Filliter C, et al. Anti-TNF therapy and the risk of herpes zoster among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2022;28:176\u201382.","journal-title":"Inflamm Bowel Dis"},{"key":"1203_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.780","volume":"11","author":"X Hong","year":"2023","unstructured":"Hong X, Xiao Y, Xu L, et al. Risk of hepatitis\u00a0B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: a meta-analysis. Immun Inflamm Dis. 2023;11:e780.","journal-title":"Immun Inflamm Dis"},{"key":"1203_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/liv.15793","volume":"44","author":"MH Kuo","year":"2024","unstructured":"Kuo MH, Tseng C-W, Ko P-H, et al. HBV reactivation in HBsAg-\/HBcAb+ rheumatoid arthritis patients receiving biologic\/targeted synthetic DMARDs. Liver Int. 2024;44:497\u2013507.","journal-title":"Liver Int"},{"key":"1203_CR41","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3899\/jrheum.140853","volume":"42","author":"KJ Aaltonen","year":"2015","unstructured":"Aaltonen KJ, Joensuu JT, Virkki L, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015;42:372\u20138.","journal-title":"J Rheumatol"},{"key":"1203_CR42","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther"},{"key":"1203_CR43","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR44","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020;2:e84-98.","journal-title":"Lancet Rheumatol"},{"key":"1203_CR45","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157:1047\u201355.","journal-title":"JAMA Dermatol"},{"key":"1203_CR46","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"A-R Balanescu","year":"2022","unstructured":"Balanescu A-R, Citera G, Pascual-Ramos V, et al. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022;81:1491\u2013503.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR47","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"1203_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.992713","volume":"13","author":"A Vassilopoulos","year":"2022","unstructured":"Vassilopoulos A, Shehadeh F, Benitez G, et al. The incidence of opportunistic infections in patients with psoriatic arthritis treated with biologic and targeted synthetic agents: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 992713.","journal-title":"Front Pharmacol"},{"key":"1203_CR49","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.cgh.2022.01.013","volume":"20","author":"D Cheng","year":"2022","unstructured":"Cheng D, Kochar BD, Cai T, Ananthakrishnan AN. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2022;20:2366-2372.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1203_CR50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","volume":"9","author":"GR Burmester","year":"2022","unstructured":"Burmester GR, Winthrop K, Blanco R, et al. Safety profile of upadacitinib up to 3\u00a0years in psoriatic arthritis: an integrated analysis of two pivotal phase\u00a03 trials. Rheumatol Ther. 2022;9:521\u201339.","journal-title":"Rheumatol Ther"},{"key":"1203_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, et al. Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase\u00a0III clinical trials. Ann Rheum Dis. 2022;81:206\u201313.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR52","doi-asserted-by":"publisher","first-page":"204062232312062","DOI":"10.1177\/20406223231206225","volume":"14","author":"H-Y Chiu","year":"2023","unstructured":"Chiu H-Y, Hung Y-T, Huang Y-H. Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials. Ther Adv Chronic Dis. 2023;14:20406223231206224.","journal-title":"Ther Adv Chronic Dis"},{"key":"1203_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-023-03111-w","volume":"25","author":"SR Choi","year":"2023","unstructured":"Choi SR, Shin A, Ha Y-J, et al. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2023;25:129.","journal-title":"Arthritis Res Ther"},{"key":"1203_CR54","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40257-023-00785-5","volume":"24","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Silverberg JI, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with severe and\/or difficult-to-treat atopic dermatitis: a post hoc analysis of the randomized phase\u00a03 JADE COMPARE trial. Am J Clin Dermatol. 2023;24:609\u201321.","journal-title":"Am J Clin Dermatol"},{"key":"1203_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02732-6","author":"E Mysler","year":"2024","unstructured":"Mysler E, Burmester GR, Saffore CD, et al. Safety of upadacitinib in immune-mediated inflammatory diseases: systematic literature review of indirect and direct treatment comparisons of randomized controlled trials. Adv Ther. 2024. https:\/\/doi.org\/10.1007\/s12325-023-02732-6.","journal-title":"Adv Ther"},{"key":"1203_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, van den Reek JMPA, Bruno M, et al. Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13: 100266.","journal-title":"Lancet Reg Health Eur"},{"key":"1203_CR57","doi-asserted-by":"publisher","first-page":"1046352","DOI":"10.3389\/fimmu.2022.1046352","volume":"13","author":"M Liu","year":"2022","unstructured":"Liu M, Wang H, Liu L, et al. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: a systematic review and meta-analysis. Front Immunol. 2022;13:1046352.","journal-title":"Front Immunol"},{"key":"1203_CR58","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/pds.5132","volume":"29","author":"C Srinivas","year":"2020","unstructured":"Srinivas C, Odsbu I, Linder M. Risk of common infections among individuals with psoriasis in Sweden: a nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf. 2020;29:1562\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1203_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","volume":"157","author":"BE Elewski","year":"2021","unstructured":"Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157:43\u201351.","journal-title":"JAMA Dermatol"},{"key":"1203_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.15242","volume":"33","author":"RG Langley","year":"2019","unstructured":"Langley RG, Kimball AB, Nak H, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33:333\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR61","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatol (Oxford). 2020;59:3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"key":"1203_CR62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40261-017-0500-9","volume":"37","author":"A Attia","year":"2017","unstructured":"Attia A, Abushouk AI, Ahmed H, et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig. 2017;37:439\u201351.","journal-title":"Clin Drug Investig"},{"key":"1203_CR63","doi-asserted-by":"publisher","first-page":"adv00683","DOI":"10.2340\/actadv.v102.1993","volume":"102","author":"K Reich","year":"2022","unstructured":"Reich K, Tha\u00e7i D, Stingl G, et al. Safety of brodalumab in plaque psoriasis: integrated pooled data from five clinical trials. Acta Derm Venereol. 2022;102:adv00683.","journal-title":"Acta Derm Venereol"},{"key":"1203_CR64","doi-asserted-by":"publisher","first-page":"204062232311631","DOI":"10.1177\/20406223231163110","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li S, Bai J, et al. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Ther Adv Chronic Dis. 2023;14:20406223231163110.","journal-title":"Ther Adv Chronic Dis"},{"key":"1203_CR65","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled data from up to three years of treatment in randomized phase\u00a03 trials. Br J Dermatol. 2024;190:477\u201385.","journal-title":"Br J Dermatol"},{"key":"1203_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670398","volume":"12","author":"Y Ru","year":"2021","unstructured":"Ru Y, Ding X, Luo Y, et al. Adverse events associated with anti-IL-23 agents: clinical evidence and possible mechanisms. Front Immunol. 2021;12:670398.","journal-title":"Front Immunol"},{"key":"1203_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/bjd\/ljad115","volume":"189","author":"MG Lebwohl","year":"2023","unstructured":"Lebwohl MG, Merola JF, Rowland K, et al. Safety of guselkumab treatment for up to 5\u00a0years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure. Br J Dermatol. 2023;189:42\u201352.","journal-title":"Br J Dermatol"},{"key":"1203_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase\u00a0II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47:39\u201357.","journal-title":"Drug Saf"},{"key":"1203_CR69","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186:466\u201375.","journal-title":"Br J Dermatol"},{"key":"1203_CR70","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up. J Am Acad Dermatol. 2023;89:1149\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR71","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase\u00a0III clinical trials (reSURFACE 1 and reSURFACE 2) through 148\u00a0weeks. Br J Dermatol. 2020;182:605\u201317.","journal-title":"Br J Dermatol"},{"key":"1203_CR72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, et al. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37:85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR73","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","volume":"66","author":"KB Gordon","year":"2012","unstructured":"Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase\u00a0II and III clinical trials. J Am Acad Dermatol. 2012;66:742\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR74","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jaad.2019.12.033","volume":"82","author":"SI Cho","year":"2020","unstructured":"Cho SI, Kang S, Kim YE, et al. Ustekinumab does not increase tuberculosis risk: results from a national database in South Korea. J Am Acad Dermatol. 2020;82:1243\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR75","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","volume":"55","author":"T Kullenberg","year":"2016","unstructured":"Kullenberg T, L\u00f6fqvist M, Leinonen M, et al. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatol (Oxford). 2016;55:1499\u2013506.","journal-title":"Rheumatol (Oxford)"},{"key":"1203_CR76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.rbr.2016.07.008","volume":"56","author":"VP Cabral","year":"2016","unstructured":"Cabral VP, de Andrade CAF, Passos SRL, et al. Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies. Rev Bras Reumatol. 2016;56:543\u201350.","journal-title":"Rev Bras Reumatol"},{"key":"1203_CR77","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00296-018-4041-1","volume":"38","author":"S Nikfar","year":"2018","unstructured":"Nikfar S, Saiyarsarai P, Tigabu BM, Abdollahi M. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int. 2018;38:1363\u201383.","journal-title":"Rheumatol Int"},{"key":"1203_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001663","volume":"7","author":"UA Walker","year":"2021","unstructured":"Walker UA, Tilson HH, Hawkins PN, et al. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the \u03b2-Confident Registry. RMD Open. 2021;7: e001663.","journal-title":"RMD Open"},{"key":"1203_CR79","doi-asserted-by":"publisher","first-page":"1114207","DOI":"10.3389\/fped.2023.1114207","volume":"11","author":"E Alexeeva","year":"2023","unstructured":"Alexeeva E, Krekhova E, Dvoryakovskaya T, et al. Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: a single-centre cohort study using routinely collected health data. Front Pediatr. 2023;11:1114207.","journal-title":"Front Pediatr"},{"key":"1203_CR80","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.clinthera.2012.09.009","volume":"34","author":"HM Hoffman","year":"2012","unstructured":"Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther. 2012;34:2091\u2013103.","journal-title":"Clin Ther"},{"key":"1203_CR81","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/jvh.12402","volume":"22","author":"L Mozessohn","year":"2015","unstructured":"Mozessohn L, Chan KKW, Feld JJ, Hicks LK. Hepatitis\u00a0B reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepatol. 2015;22:842\u20139.","journal-title":"J Viral Hepatol"},{"key":"1203_CR82","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","volume":"78","author":"KL Gr\u00f8n","year":"2019","unstructured":"Gr\u00f8n KL, Arkema EV, Glintborg B, et al. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Ann Rheum Dis. 2019;78:320\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR83","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/1756-185X.13596","volume":"22","author":"Y Shi","year":"2019","unstructured":"Shi Y, Wu Y, Ren Y, et al. Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2019;22:1361\u201370.","journal-title":"Int J Rheum Dis"},{"key":"1203_CR84","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/rheumatology\/kez530","volume":"59","author":"KL Gr\u00f8n","year":"2020","unstructured":"Gr\u00f8n KL, Glintborg B, N\u00f8rgaard M, et al. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. Rheumatol (Oxford). 2020;59:1949\u201356.","journal-title":"Rheumatol (Oxford)"},{"key":"1203_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102505","volume":"19","author":"C Thery-Casari","year":"2020","unstructured":"Thery-Casari C, Euvrard R, Mainbourg S, et al. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: a meta-analysis. Autoimmun Rev. 2020;19: 102505.","journal-title":"Autoimmun Rev"},{"key":"1203_CR86","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/bjd\/ljac118","volume":"188","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Amber KT, Ludwig RJ. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol. 2023;188:499\u2013505.","journal-title":"Br J Dermatol"},{"key":"1203_CR87","first-page":"308","volume":"28","author":"Z Pouransiri","year":"2023","unstructured":"Pouransiri Z, Assadi F, Mohkam M, et al. A systematic review and meta-analysis of rituximab-associated infections among children and adolescents with glomerular disease: focus on the risk of infections. J Pediatr Pharmacol Ther. 2023;28:308\u201315.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1203_CR88","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.ejim.2017.11.014","volume":"50","author":"K Alexandre","year":"2018","unstructured":"Alexandre K, Ingen-Housz-Oro S, Versini M, et al. Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: report of 11 cases and review of the literature. Eur J Intern Med. 2018;50:e23\u20134.","journal-title":"Eur J Intern Med"},{"key":"1203_CR89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","volume":"78","author":"P Fleming","year":"2018","unstructured":"Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78:62\u201369.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR90","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/ijms21030889","volume":"21","author":"K Ando","year":"2020","unstructured":"Ando K, Tanaka A, Sagara H. Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: a systematic review. Int J Mol Sci. 2020;21:889.","journal-title":"Int J Mol Sci"},{"key":"1203_CR91","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","volume":"84","author":"A-S Halling","year":"2021","unstructured":"Halling A-S, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;84:139\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR92","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","volume":"84","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Kim SC, Wyss R, et al. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study. J Am Acad Dermatol. 2021;84:300\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR93","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/1744666X.2023.2271666","volume":"20","author":"M Marko","year":"2024","unstructured":"Marko M, Pawliczak R. Skin infections during dupilumab monotherapy in moderate-to-severe atopic dermatitis\u2014a meta-analysis of randomized clinical trials. Expert Rev Clin Immunol. 2024;20:121\u201334.","journal-title":"Expert Rev Clin Immunol"},{"key":"1203_CR94","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","volume":"87","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Langley RG, Lacour J-P, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022;87:815\u201324.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR95","doi-asserted-by":"publisher","first-page":"8191","DOI":"10.1038\/srep08191","volume":"5","author":"T Lai","year":"2015","unstructured":"Lai T, Wang S, Xu Z, et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci Rep. 2015;5:8191.","journal-title":"Sci Rep"},{"key":"1203_CR96","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.aller.2019.05.003","volume":"47","author":"NPM Rubini","year":"2019","unstructured":"Rubini NPM, Ensina LFC, Silva EMK, et al. Effectiveness and safety of omalizumab in the treatment of chronic spontaneous urticaria: systematic review and meta-analysis. Allergol Immunopathol (Madr). 2019;47:515\u201322.","journal-title":"Allergol Immunopathol (Madr)"},{"key":"1203_CR97","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1097\/MJT.0000000000000912","volume":"27","author":"H-X Jia","year":"2020","unstructured":"Jia H-X, He Y-L. Efficacy and safety of omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis of randomized controlled trials. Am J Ther. 2020;27:e455\u201367.","journal-title":"Am J Ther"},{"key":"1203_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825312","volume":"13","author":"J Liang","year":"2022","unstructured":"Liang J, Hu F, Dan M, et al. Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials. Front Immunol. 2022;13: 825312.","journal-title":"Front Immunol"},{"key":"1203_CR99","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1684\/ejd.2023.4551","volume":"33","author":"K Miyawaki","year":"2023","unstructured":"Miyawaki K, Nakashima C, Otsuka A. Real-world effectiveness and safety of nemolizumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study. Eur J Dermatol. 2023;33:691\u20132.","journal-title":"Eur J Dermatol"},{"key":"1203_CR100","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-020-02326-5","volume":"22","author":"G Armaroli","year":"2020","unstructured":"Armaroli G, Klein A, Ganser G, et al. Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Res Ther. 2020;22:258.","journal-title":"Arthritis Res Ther"},{"key":"1203_CR101","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5152\/eurjrheum.2022.22028","volume":"10","author":"F Broca","year":"2023","unstructured":"Broca F, Souchaud-Debouverie O, Liuu E, et al. Severe infections in patients treated with tocilizumab for systemic diseases other than rheumatoid arthritis: a retrospective multicenter observational study. Eur J Rheumatol. 2023;10:18\u201322.","journal-title":"Eur J Rheumatol"},{"key":"1203_CR102","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/v16010078","volume":"16","author":"P-H Ko","year":"2024","unstructured":"Ko P-H, Kuo MH, Kao I-T, et al. The risk of hepatitis\u00a0B virus reactivation in rheumatoid arthritis patients receiving tocilizumab: a systematic review and meta-analysis. Viruses. 2024;16:78.","journal-title":"Viruses"},{"key":"1203_CR103","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatol (Oxford). 2019;58:1755\u201366.","journal-title":"Rheumatol (Oxford)"},{"key":"1203_CR104","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini F, Blandizzi C, Niccoli L, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020;19:861\u201372.","journal-title":"Expert Opin Drug Saf"},{"key":"1203_CR105","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158:1554-1573.e12.","journal-title":"Gastroenterology"},{"key":"1203_CR106","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15636","volume":"35","author":"H Wan","year":"2022","unstructured":"Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35:e15636.","journal-title":"Dermatol Ther"},{"key":"1203_CR107","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Marques FB. The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol. 2022;28:e407\u201314.","journal-title":"J Clin Rheumatol"},{"key":"1203_CR108","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.reuma.2021.06.004","volume":"18","author":"CO S\u00e1nchez Gonz\u00e1lez","year":"2022","unstructured":"S\u00e1nchez Gonz\u00e1lez CO, Nieto Gonz\u00e1lez JC. JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature. Reumatol Clin. 2022;18:453\u20138.","journal-title":"Reumatol Clin"},{"key":"1203_CR109","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","volume":"43","author":"CG Gialouri","year":"2023","unstructured":"Gialouri CG, Moustafa S, Thomas K, et al. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int. 2023;43:421\u201335.","journal-title":"Rheumatol Int"},{"key":"1203_CR110","doi-asserted-by":"publisher","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","volume":"14","author":"Q Xu","year":"2023","unstructured":"Xu Q, He L, Yin Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1241954.","journal-title":"Front Pharmacol"},{"key":"1203_CR111","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","volume":"42","author":"F Yang","year":"2023","unstructured":"Yang F, Lu C, Wang Y, et al. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023;42:1593\u2013605.","journal-title":"Clin Rheumatol"},{"key":"1203_CR112","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/jdv.19426","volume":"38","author":"S Yoon","year":"2024","unstructured":"Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38:52\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR113","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase\u00a0II and phase\u00a0III clinical trial program. Am J Clin Dermatol. 2021;22:693\u2013707.","journal-title":"Am J Clin Dermatol"},{"key":"1203_CR114","doi-asserted-by":"publisher","first-page":"734","DOI":"10.5114\/ada.2023.133959","volume":"40","author":"L Zeng","year":"2023","unstructured":"Zeng L, Feng S, Yao L, et al. Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. Postepy Dermatol Alergol. 2023;40:734\u201340.","journal-title":"Postepy Dermatol Alergol"},{"key":"1203_CR115","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","volume":"151","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase\u00a03 studies. J Allergy Clin Immunol. 2023;151:172\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"1203_CR116","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3\u00a0years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81:335\u201343.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR117","doi-asserted-by":"publisher","first-page":"2161812","DOI":"10.1080\/09546634.2022.2161812","volume":"34","author":"T Bieber","year":"2023","unstructured":"Bieber T, Katoh N, Simpson EL, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6\u00a0years and up to 3.9\u00a0years of treatment: an updated integrated analysis of eight clinical trials. J Dermatol Treat. 2023;34:2161812.","journal-title":"J Dermatol Treat"},{"key":"1203_CR118","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/03007995.2022.2135838","volume":"39","author":"AM Mahmoud","year":"2023","unstructured":"Mahmoud AM. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2023;39:249\u201357.","journal-title":"Curr Med Res Opin"},{"key":"1203_CR119","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93:339\u201347.","journal-title":"Am J Hematol"},{"key":"1203_CR120","first-page":"663","volume":"26","author":"Q Luo","year":"2021","unstructured":"Luo Q, Xiao Z, Peng L. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis. Hematol Amst Neth. 2021;26:663\u20139.","journal-title":"Hematol Amst Neth"},{"key":"1203_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954268","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Huo W-X, Yang Y, et al. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis. Front Immunol. 2022;13:954268.","journal-title":"Front Immunol"},{"key":"1203_CR122","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase\u00a03 studies. J Am Acad Dermatol. 2023;88:1008\u201316.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR123","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park S-H, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1203_CR124","doi-asserted-by":"publisher","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5\u00a0years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395.","journal-title":"RMD Open"},{"key":"1203_CR125","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022;28:32\u201340.","journal-title":"Inflamm Bowel Dis"},{"key":"1203_CR126","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/ibd\/izac063","volume":"29","author":"KL Winthrop","year":"2023","unstructured":"Winthrop KL, Vermeire S, Long MD, et al. Long-term risk of herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2023;29:85\u201396.","journal-title":"Inflamm Bowel Dis"},{"key":"1203_CR127","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","volume":"17","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, D\u2019Haens GR, Sands BE, et al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8\u00a0years of safety data from the global clinical programme. J Crohns Colitis. 2023;17:338\u201351.","journal-title":"J Crohns Colitis"},{"key":"1203_CR128","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1203_CR129","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/bjd\/ljae014","volume":"190","author":"M Lebwohl","year":"2024","unstructured":"Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase\u00a03 POETYK trials. Br J Dermatol. 2024;190:668\u201379.","journal-title":"Br J Dermatol"},{"key":"1203_CR130","doi-asserted-by":"crossref","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol. 2024;25(2):299\u2013314.","DOI":"10.1007\/s40257-024-00846-3"},{"key":"1203_CR131","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1111\/jdv.19378","volume":"37","author":"JI Olydam","year":"2023","unstructured":"Olydam JI, Schl\u00f6sser AR, Custurone P, et al. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37:2537\u201342.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR132","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00277-018-3405-7","volume":"98","author":"H Gill","year":"2019","unstructured":"Gill H, Leung GMK, Seto W-K, Kwong Y-L. Risk of viral reactivation in patients with occult hepatitis\u00a0B virus infection during ruxolitinib treatment. Ann Hematol. 2019;98:215\u20138.","journal-title":"Ann Hematol"},{"key":"1203_CR133","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/16078454.2021.1945234","volume":"26","author":"M-H Duan","year":"2021","unstructured":"Duan M-H, Cao X-X, Chang L, Zhou D-B. Risk of hepatitis\u00a0B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. Hematology. 2021;26:460\u20134.","journal-title":"Hematology"},{"key":"1203_CR134","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","volume":"23","author":"N Iwamoto","year":"2021","unstructured":"Iwamoto N, Sato S, Kurushima S, et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther. 2021;23:197.","journal-title":"Arthritis Res Ther"},{"key":"1203_CR135","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/1756-185X.14217","volume":"24","author":"S-T Wang","year":"2021","unstructured":"Wang S-T, Tseng C-W, Hsu C-W, et al. Reactivation of hepatitis\u00a0B virus infection in patients with rheumatoid arthritis receiving tofacitinib. Int J Rheum Dis. 2021;24:1362\u20139.","journal-title":"Int J Rheum Dis"},{"key":"1203_CR136","doi-asserted-by":"publisher","first-page":"2307489","DOI":"10.1080\/09546634.2024.2307489","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. J Dermatol Treat. 2024;35:2307489.","journal-title":"J Dermatol Treat"},{"key":"1203_CR137","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/jdv.16866","volume":"35","author":"M Nogueira","year":"2021","unstructured":"Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis\u2014time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35:824\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1203_CR138","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1177\/13524585221101138","volume":"28","author":"J Lycke","year":"2022","unstructured":"Lycke J, Svenningsson A. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: commentary. Mult Scler. 2022;28:1177\u20138.","journal-title":"Mult Scler"},{"key":"1203_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152362","volume":"65","author":"Y-E Kim","year":"2024","unstructured":"Kim Y-E, Kim Y-J, Jeong DH, et al. Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: a nationwide population-based study in South Korea. Semin Arthritis Rheum. 2024;65:152362.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01203-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01203-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T11:26:47Z","timestamp":1724066807000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01203-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":139,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1203"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01203-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Miguel Mansilla-Polo and Daniel Morgado-Carrasco have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In terms of ethics, this article does not require ethics committee approval as it is based on previously conducted studies and does not include any new human or animal studies conducted by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}